Logo

BerGenBio and Tempus Collaborate to Advance the Development of STK11m to Treat NSCLC

Share this
BerGenBio and Tempus

M&A

BerGenBio and Tempus Collaborate to Advance the Development of STK11m to Treat NSCLC

Shots:

  • BerGenBio entered into a collaboration with Tempus to advance the development of selective AXL inhibitor bemcentinib as a 1L treatment for NSCLC-induced patients with STK11 mutations (STK11m)
  • To support BerGenBio's study, the collaboration will provide access to Tempus' tailored clinical and molecular data. Tempus’ AI-enabled platform will allow BerGenBio to analyze the data and enhance understanding of the genomic landscape and treatment responses
  • Currently, the drug is evaluating in the BGBC016 P-Ib/IIa study assessing the advantage of adding bemcentinib to the current SoC medication (immunotx. + doublet CT) in people with poor outcomes

Ref: BerGenBio | Image: BerGenBio & Tempus

Related News:- BerGenBio Reports P-II Trial Results of BGB324 (bemcentinib) as 2L Treatment of Non-Small Cell Lung Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Prince Giri

An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions